Clinical Trial Results: Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks [Phase 3]

View source ↗

Summary

Phase 3 results for garadacimab (CSL312) in long-term prophylaxis of hereditary angioedema indicate safety and efficacy outcomes from completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Garadacimab (garadacimab)

Snippet

Sponsor: CSL Behring | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2026-06-02